Company Overview - In 2024, the company achieved total revenue of 4.758 billion yuan, a year-on-year increase of 0.98%, and a net profit of 288 million yuan, a year-on-year decrease of 35.37% [1] - The company focuses on the development, design, production, and sales of small household appliances under its own brand "Xiaoxiong," with over 90 self-developed categories and more than 1,000 product models [1] - From 2016 to 2024, the company's revenue compound annual growth rate exceeded 18% [1] International Market Strategy - Currently, overseas sales account for 6.68 billion yuan, representing 14.04% of total revenue, with a broad distribution of overseas customers across regions such as Japan, South Korea, Southeast Asia, Europe, and North America [1][2] - The company plans to focus on major markets for breakthroughs, emphasizing self-owned brands and cross-border e-commerce while also enhancing product development tailored to overseas demand [2] Sales Channels and Operations - Online sales account for nearly 76% of total sales, with the company acknowledging a lag in expanding offline channels [2] - The company aims to build comprehensive marketing capabilities and enhance operational efficiency through a digital and refined management system for offline channels [2] Acquisition and Integration - The company completed the acquisition of Roman Smart in 2024, with the integration of the Roman project already in place, where the original Roman team focuses on OEM business while the brand operations are managed by the company's team [2] Industry Outlook - The company anticipates that policies such as replacement incentives will stimulate demand in the small household appliance market, leading to the release of pent-up demand [3] - Trends such as "one-person economy," "aesthetic economy," and "silver economy" are driving further segmentation of small appliance demand, with products featuring stronger attributes of "self-care," "innovation," "health," and "intelligence" emerging to meet consumer desires for personalized and high-quality lifestyles [3]

Group 1: Industry Overview - The beauty and personal care sector experienced a significant increase, with the index reaching a two-year high and the sector rising nearly 2% on May 9 [1] - Several companies within the sector reported notable growth in their financial performance, with leading company Proya (珀莱雅) achieving a revenue of 2.359 billion yuan, a year-on-year increase of 8.13%, and a net profit of 390 million yuan, up 28.87% [1] - Other companies in the sector, such as Nobon (诺邦股份), Qingsong (青松股份), and Jinbo (锦波股份), reported growth rates exceeding 50% in the first quarter [1] Group 2: Key Trends and Consumer Behavior - According to a report by Mintel, the trend of "Beauty in Body and Mind" is one of the three major trends influencing the global beauty and personal care industry in the coming years [2] - The rise of the "颜值经济" (beauty economy) and "悦己潮流" (self-pleasure trend) has led consumers to purchase functional skincare products, trendy makeup, and home fragrances for self-healing purposes [2] Group 3: Notable Companies in the Sector - Proya focuses on the research, production, and sales of cosmetic products, with brands including "Proya," "Caitang," "Off&Relax," and "Yuefuti" [2] - Shanghai Jahwa (上海家化) specializes in the research, production, and sales of daily chemical products, including personal care and beauty products [2] - Furuida (福瑞达) has transitioned into the health industry through acquisitions, creating a full industry chain from hyaluronic acid raw materials to products [2] - Huaxi Biological (华熙生物) is a leading high-tech enterprise in the production of hyaluronic acid through microbial fermentation technology [2] - Betaini (贝泰妮) operates a subsidiary focused on medical beauty services, including laser and micro-needle treatments [2] - Shuiyang (水羊股份) has launched a light medical beauty brand, primarily sold through online platforms [2] - Nobon produces water-jet non-woven materials used in beauty care, industrial materials, and medical supplies [2] - Marubi (丸美生物) specializes in the research, design, production, and sales of cosmetics, focusing on eye care, skincare, and cleansing products [2]

美瞳 是一种用于改变或增强眼睛颜色的镜片，可实现从自然柔和到鲜明抢眼的多种视觉效果。日抛型美瞳专为单日佩戴设计，使用后无需清洁 护理，直接弃置，更加便捷卫生。 日抛型美瞳作为结合功能性与时尚性的光学产品，其行业发展呈现出快速、细分和消费年轻化的趋势。首先，随着消费者对佩戴舒适度与眼部 健康关注度的提升，日抛型产品因其使用周期短、清洁便利、不易滋生细菌等优势，逐渐成为市场主流。与传统月抛或年抛美瞳相比，日抛型 更适合日常通勤、短期造型或临时搭配使用，有效降低了感染风险，也满足了现代消费者对高效、安全、便捷产品的偏好。与此同时，品牌方 不断推出各类新花色、自然系或特效系镜片，紧贴潮流审美，推动产品向个性化、场景化方向发展。 据 QYResearch 调研团队最新报告 " 全球日抛型美瞳市场报告 2025-2031" 显示， 预计 2031 年全球日抛型美瞳市场规模将达到 35.2 亿美元 ，未 来几年年复合增长率 CAGR 为 11.3% 。 市场驱动因素主要来自三个方面：首先是 " 颜值经济 " 的兴起，尤其在社交媒体的带动下，美瞳不再只是矫正视力的工具，更成为日常妆容的 一部分，引导消费者追求精致外观与自我表 ...

Core Viewpoint - The article discusses the internal turmoil and strategic challenges faced by Huaxi Biological, particularly in light of its declining performance and the need for significant internal reforms to address corruption and strategic misalignment [3][4][5]. Group 1: Internal Challenges and Strategic Issues - Huaxi Biological's CEO Zhao Yan issued an ultimatum for employees involved in corruption to resign by March 31, indicating a critical need for internal restructuring [3]. - The company is experiencing a significant decline in revenue and profits, with a reported drop of over 70% in profits for 2024, highlighting the urgency of the situation [3][4]. - The internal issues are compounded by strategic missteps, particularly the failure to adapt to market changes and the overproduction of hyaluronic acid, leading to an oversupply situation [9][15]. Group 2: Market Dynamics and Competitive Landscape - The hyaluronic acid market has shifted from a scarcity to an oversupply, with average prices dropping from 210 RMB per gram in 2017 to 124 RMB in 2021, a decline of 41% [9]. - New competitors in the collagen market have emerged, capturing consumer interest and market share, which has further pressured Huaxi Biological's traditional hyaluronic acid business [11][12]. - The company has been slow to diversify into collagen products, missing out on a significant market opportunity that could have alleviated current pressures [12][15]. Group 3: Financial Performance and Cost Management - Huaxi Biological's sales and management expenses have surged from 38.23% in 2018 to 61.72% in 2023, with sales expenses alone increasing from 284 million RMB to 2.842 billion RMB during the same period [27]. - Despite maintaining a high gross margin of around 73%, the net profit margin has plummeted from 33.56% in 2018 to approximately 9.27% in 2024, indicating severe profitability issues [27][28]. - The company's strategy to cut costs and improve profitability through internal reforms may provide short-term relief, but long-term success will depend on genuine operational improvements [29][30].